Replies to post #162 on Equity Field Notes from temporal sources

[DanWebzster]

IFRX is a recent IPO that has showed significant institutional support.

Lead program is enrolling Ph2B to study first-in-class anti-human complement factor antibody in patients with Hidranitis Suppurativa (HS).

The data for this study will be available H-1/2019.

Presently, 50% of HS patients do not respond to the only approved treatment.

5/3/18, IFRX raised $51mn in a secondary stock offering.

CCXI is in Ph3 with a treatment targeting the same receptor. Interestingly, CCXI MC is only 66% of IFRX MC.